NCT06755684

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer: a Single-center, Randomized Controlled Trial

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Peng Zhang · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation

Conditions

• EGFR
• Non-Small Cell Lung Cancer
• Locally Advanced Non-Small Cell Lung Cancer
• Pemetrexed
• Carboplatin
• Bevacizumab
• Antineoplastic Agents
• Tyrosine Kinase Inhibitor

Interventions

Type	Name	Description
DRUG	Befotertinib combined Bevacizumab	Befotertinib combined Bevacizumab
DRUG	Befotertinib combined platinum-based double chemotherapy	Befotertinib combined platinum-based double chemotherapy

Timeline

• Start date: 2024-11-07
• Primary completion: 2025-12-31
• Completion: 2028-12-31
• First posted: 2025-01-01
• Last updated: 2025-01-06

Locations

1 site across 1 country: China